Literature DB >> 10360767

Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype.

E Ricci1, G Galluzzi, G Deidda, S Cacurri, L Colantoni, B Merico, N Piazzo, S Servidei, E Vigneti, V Pasceri, G Silvestri, M Mirabella, F Mangiola, P Tonali, L Felicetti.   

Abstract

Genotype analysis by using the p13E-11 probe and other 4q35 polymorphic markers was performed in 122 Italian facioscapulohumeral muscular dystrophy families and 230 normal controls. EcoRI-BlnI double digestion was routinely used to avoid the interference of small EcoRI fragments of 10qter origin that were found in 15% of the controls. An EcoRI fragment ranging between 10 and 28 kb that was resistant to BlnI digestion was detected in 114 of 122 families (93%) comprising 76 familial and 38 isolated cases. Among the unaffected individuals, 3 were somatic mosaics and 7, carrying an EcoRI fragment larger than 20 kb, could be rated as nonpenetrant gene carriers. In a cohort of 165 patients with facioscapulohumeral muscular dystrophy we found an inverse correlation between fragment size and clinical severity. A severe lower limb involvement was observed in 100% of patients with an EcoRI fragment size of 10 to 13 kb (1-2 KpnI repeats left), in 53% of patients with a fragment size of 16 to 20 kb (3-4 KpnI repeats left), and in 19% of patients with a fragment size larger than 21 kb (>4 KpnI repeats left). Our results confirm that the size of the fragment is a major factor in determining the facioscapulohumeral muscular dystrophy phenotype and that it has an impact on clinical prognosis and genetic counseling of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10360767     DOI: 10.1002/1531-8249(199906)45:6<751::aid-ana9>3.0.co;2-m

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  98 in total

1.  Distinguishing the 4qA and 4qB variants is essential for the diagnosis of facioscapulohumeral muscular dystrophy in the Chinese population.

Authors:  Zhi-Qiang Wang; Ning Wang; Silvere van der Maarel; Shen-Xing Murong; Zhi-Ying Wu
Journal:  Eur J Hum Genet       Date:  2010-08-25       Impact factor: 4.246

2.  Clinical features of facioscapulohumeral muscular dystrophy 2.

Authors:  J C de Greef; R J L F Lemmers; P Camaño; J W Day; S Sacconi; M Dunand; B G M van Engelen; S Kiuru-Enari; G W Padberg; A L Rosa; C Desnuelle; S Spuler; M Tarnopolsky; S L Venance; R R Frants; S M van der Maarel; R Tawil
Journal:  Neurology       Date:  2010-10-26       Impact factor: 9.910

3.  Cephalometric findings in facioscapulohumeral muscular dystrophy patients with obstructive sleep apneas.

Authors:  Giacomo Della Marca; Francesca Pantanali; Roberto Frusciante; Emanuele Scarano; Alessandro Cianfoni; Lea Calò; Serena Dittoni; Catello Vollono; Anna Losurdo; Elisa Testani; Salvatore Colicchio; Valentina Gnoni; Elisabetta Iannaccone; Benedetto Farina; Tommaso Pirronti; Pietro A Tonali; Enzo Ricci
Journal:  Sleep Breath       Date:  2010-02-20       Impact factor: 2.816

4.  Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI.

Authors:  David B Olsen; Peter Gideon; Tina Dysgaard Jeppesen; John Vissing
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

5.  Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity.

Authors:  Emanuela Teveroni; Marsha Pellegrino; Sabrina Sacconi; Patrizia Calandra; Isabella Cascino; Stefano Farioli-Vecchioli; Angela Puma; Matteo Garibaldi; Roberta Morosetti; Giorgio Tasca; Enzo Ricci; Carlo Pietro Trevisan; Giuliana Galluzzi; Alfredo Pontecorvi; Marco Crescenzi; Giancarlo Deidda; Fabiola Moretti
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

6.  The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.

Authors:  Sabrina Sacconi; Richard J L F Lemmers; Judit Balog; Patrick J van der Vliet; Pauline Lahaut; Merlijn P van Nieuwenhuizen; Kirsten R Straasheijm; Rashmie D Debipersad; Marianne Vos-Versteeg; Leonardo Salviati; Alberto Casarin; Elena Pegoraro; Rabi Tawil; Egbert Bakker; Stephen J Tapscott; Claude Desnuelle; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

7.  Role of the Chromosome Architectural Factor SMCHD1 in X-Chromosome Inactivation, Gene Regulation, and Disease in Humans.

Authors:  Chen-Yu Wang; Harrison Brand; Natalie D Shaw; Michael E Talkowski; Jeannie T Lee
Journal:  Genetics       Date:  2019-08-16       Impact factor: 4.562

8.  Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level.

Authors:  Rinse Klooster; Kirsten Straasheijm; Bharati Shah; Janet Sowden; Rune Frants; Charles Thornton; Rabi Tawil; Silvère van der Maarel
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

9.  New multiplex PCR-based protocol allowing indirect diagnosis of FSHD on single cells: can PGD be offered despite high risk of recombination?

Authors:  Mouna Barat-Houari; Karine Nguyen; Rafaëlle Bernard; Céline Fernandez; Catherine Vovan; Corinne Bareil; Philippe Khau Van Kien; Delphine Thorel; Sylvie Tuffery-Giraud; Francis Vasseur; Shahram Attarian; Jean Pouget; Anne Girardet; Nicolas Lévy; Mireille Claustres
Journal:  Eur J Hum Genet       Date:  2009-11-25       Impact factor: 4.246

10.  DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferation.

Authors:  Eugénie Ansseau; Dalila Laoudj-Chenivesse; Aline Marcowycz; Alexandra Tassin; Céline Vanderplanck; Sébastien Sauvage; Marietta Barro; Isabelle Mahieu; Axelle Leroy; India Leclercq; Véronique Mainfroid; Denise Figlewicz; Vincent Mouly; Gillian Butler-Browne; Alexandra Belayew; Frédérique Coppée
Journal:  PLoS One       Date:  2009-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.